Azora Therapeutics, Inc. (AZR) Reports $64.6M Q3 Loss, Including $57.1M Non-Cash Charge

Azora reported a Q3 2026 net loss of $64.6M, or $4.52 per share, versus $1.8M, or $2.02 per share, in Q3 2025; the 2026 loss included a $57.1M non-cash warrant-liability charge. Cash was $22.0M versus $28.7M at June 30, 2026.Material DetailsContext by AI AnalystThe results show a clinical-stage com…